Vytorin/Zetia Drug Marketing
Result: $41.5 million settlement
Year: 2010
In re Vytorin/Zetia Marketing, Sales Practices & Products Liability Litigation
Lieff Cabraser served on the Executive Committee of Plaintiffs’ Steering Committee in multidistrict litigation arising out of the sale and marketing of Vytorin and Zetia, two cholesterol drugs marketed and sold by Merck/Schering-Plough Pharmaceuticals, a joint venture between Merck & Co., Inc. and Schering-Plough Corp.
Plaintiffs alleged that Vytorin and Zetia were marketed as being more effective than other anti-cholesterol drugs and were sold at higher prices when they were no more effective than less expensive anti-cholesterol drugs.
On February 9, 2010, the Court granted final approval to a $41.5 million settlement for persons and entities which paid for these drugs between November 2002 and the date of final approval of the settlement.
Civil Litigation News
San Francisco Schools Receive Financial Boost From Settlement With JUUL
As reported by the S.F. Chronicle, the San Francisco Unified School District has been awarded a substantial $24.65 million payment from vaping
Final Approval Granted to Historic $235M Settlement with Altria in National JUUL Youth E-Cigarette Predatory Advertising, Addiction and Injury Litigation
On March 14, 2024, U.S. District Judge William Orrick of the Northern District of California issued an order granting final approval to a comprehensive
New York Times Spotlights Lieff Cabraser’s Recent Win on Behalf of Hawaiian Kona Coffee Farmers
The New York Times has published an exemplary piece highlighting Lieff Cabraser’s leadership in securing a pivotal victory for Kona coffee farmers
